CCM
TARA icon

Catalio Capital Management’s Protara Therapeutics TARA Stock Holding History

Catalio Capital Management’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.02M Sell
580,024
-866,230
-60% -$5.13M 0.63% 31
2025
Q4 		$7.71M Sell
1,446,254
-54,539
-4% -$303K 1.36% 29
2025
Q3 		$6.53M Sell
1,500,793
-125,577
-8% -$407K 1.21% 26
2025
Q2 		$4.93M Buy
1,626,370
+537,679
+49% +$1.85M 1.03% 24
2025
Q1 		$4.64M Hold
1,088,691
– – 1.13% 20
2024
Q4 		$5.75M Buy
+1,088,691
New +$3.52M 1.26% 24

Other funds holding TARA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Catalio Capital Management's TARA Position: Q1 2026 in Review

Catalio Capital Management reduced its Protara Therapeutics (TARA) stake by 60% in Q1 2026, selling an estimated $5.13M and leaving 580,024 shares worth $3.02M. The position accounts for 0.63% of the portfolio, ranked #31.

Catalio Capital Management first reported a position in TARA in Q4 2024 and has held it in 6 quarters since. The position peaked at $7.71M in Q4 2025. 114 funds tracked by Wall St. Rank hold TARA as of Q1 2026.

  • Catalio Capital Management held 580,024 shares of Protara Therapeutics worth $3.02M as of Q1 2026.
  • Catalio Capital Management sold 866,230 Protara Therapeutics shares in Q1 2026, an estimated $5.13M.
  • Protara Therapeutics made up 0.63% of Catalio Capital Management's portfolio in Q1 2026, its #31 holding.
  • Catalio Capital Management first reported a position in Protara Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Catalio Capital Management's Protara Therapeutics position peaked at $7.71M in Q4 2025.
  • 114 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2026.

Based on Catalio Capital Management's 13F filing for Q1 2026, filed 15 May 2026.